CN116082358B - 一类4-羟基-2-吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用 - Google Patents
一类4-羟基-2-吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN116082358B CN116082358B CN202310041169.0A CN202310041169A CN116082358B CN 116082358 B CN116082358 B CN 116082358B CN 202310041169 A CN202310041169 A CN 202310041169A CN 116082358 B CN116082358 B CN 116082358B
- Authority
- CN
- China
- Prior art keywords
- hydroxy
- fermentation
- extract
- preparation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZEZJPIDPVXJEME-UHFFFAOYSA-N 2,4-Dihydroxypyridine Chemical class OC=1C=CNC(=O)C=1 ZEZJPIDPVXJEME-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 19
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241001373664 Arthrinium sp. Species 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000000855 fermentation Methods 0.000 claims description 25
- 230000004151 fermentation Effects 0.000 claims description 25
- 229940125904 compound 1 Drugs 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000000287 crude extract Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000006073 displacement reaction Methods 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000010829 isocratic elution Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 3
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 3
- 239000004223 monosodium glutamate Substances 0.000 claims description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 238000005191 phase separation Methods 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 238000004809 thin layer chromatography Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000002024 ethyl acetate extract Substances 0.000 claims description 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 230000000259 anti-tumor effect Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 244000005700 microbiome Species 0.000 abstract description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000005100 correlation spectroscopy Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002611 lead compounds Chemical class 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 2
- 229960004671 enzalutamide Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical group 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- -1 pyridone alkaloid compounds Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类4‑羟基‑2‑吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用。本发明从节菱孢Arthrinium sp.ZSDS1‑F3中制备得到两个具有抗肿瘤活性的化合物1和2，其结构式如式(Ⅰ)所示。实验证明，化合物1和2具有良好的抗肿瘤活性，可用于开发抗肿瘤药物。本发明为开发新的抗肿瘤药物提供了备选化合物，对我国海洋微生物药物资源的开发具有重要意义。
Description
技术领域
本发明属于天然药物技术领域，具体涉及4-羟基-2-吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用。
背景技术
肿瘤是一类严重影响人类生命健康的疾病，其致死率居高不下，仅次于心脑血管疾病。目前随着人口老龄化的加剧以及环境污染等不利因素的影响，肿瘤对人类的威胁有进一步加剧的趋势。具有高度物种多样性的海洋真菌能够产生结构新颖的次生代谢产物，是发现新型抗肿瘤药物先导化合物的重要资源。加强对抗肿瘤活性生产菌株的开发研究，对筛选发掘具有抗肿瘤活性的天然产物及药源先导化合物研发具有重要意义。
发明内容
本发明的第一个目的是提供一类4-羟基-2-吡啶酮生物碱类衍生物或其药用盐，所述的4-羟基-2-吡啶酮生物碱类衍生物的结构式如式1-2任一所示。
本发明的第二个目的是提供一种制备上述的4-羟基-2-吡啶酮生物碱类衍生物的方法，所述的4-羟基-2-吡啶酮生物碱类衍生物是从节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物中分离制备得到的。
优选的，所述的制备方法，具体步骤如下：
1)制备节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物；
2)对发酵培养物进行离心，得上清发酵液和沉淀菌丝体；上清发酵液用乙酸乙酯萃取，乙酸乙酯萃取液减压浓缩得到发酵液浸膏；沉淀菌丝体用丙酮水溶液超声浸提，提取液经减压蒸馏后，再用乙酸乙酯萃取，乙酸乙酯萃取液减压浓缩得到菌丝体浸膏；合并发酵液浸膏和菌丝体浸膏，再用石油醚反复萃取，除去油脂部分，得到粗浸膏；粗浸膏用正相硅胶柱层析分离，采用CH2Cl2–MeOH按体积分数0-100％进行梯度洗脱顺序得到组分7个组分fr1～fr7；将CH2Cl2–MeOH按体积比95:5洗脱得到的组分fr4经Sephadex LH-20柱层析，以甲醇为洗脱剂，洗脱纯化后，根据薄层层析结果分析，获得6个馏分fr4-1～fr4-6；收集以二氯甲烷：甲醇＝10：1v/v作为展开剂位移值在0.4-0.6范围内的馏分fr4-3，馏分fr4-3以210、290和340nm波长做检测、采用4mL/min的流速，以乙腈：水体积比为55:45进行等梯度洗脱进行半制备高效液相分离，收集保留时间为19.2min的组分，得到化合物2，收集保留时间为28.3min的组分，得到化合物1。
优选的，所述的节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物是将节菱孢Arthrinium sp.ZSDS1-F3接入发酵培养基中发酵得到，所述的发酵培养基，每升含有：山梨醇20g，麦芽糖20g，味精10g，蛋白胨3g，磷酸二氢钾0.5g，硫酸镁0.3g，溶剂为水。
本发明的第三个目的是提供一种上述的4-羟基-2-吡啶酮生物碱类衍生物或其药用盐在制备抗肿瘤药物中的应用。
优选的，所述的抗肿瘤药物为抗前列腺癌、肺癌或肝癌的药物。
优选的，当为化合物1时，所述的抗肿瘤药物为抗前列腺癌的药物。
本发明的第四个目的是提供一种抗肿瘤药物，所述的抗肿瘤药物包含有效量的作为活性成分的上述式1-2任一所示的4-羟基-2-吡啶酮生物碱类衍生物或其药用盐，和药学上可以接受的载体。
本发明的第五个目的是提供节菱孢Arthrinium sp.ZSDS1-F3在制备4-羟基-2-吡啶酮生物碱类衍生物中的应用。
与现有技术相比，本发明具有如下有益效果：
本发明提供了一类结构新颖的4-羟基-2-吡啶酮生物碱类衍生物，该类化合物具有显著的抗肿瘤活性。其中，化合物1对前列腺癌、肺癌和肝癌具有显著的抑制活性，IC50值分别为0.53μM、3.48μM和4.78μM；特别是化合物1对前列腺癌的抗肿瘤细胞活性IC50值强于阳性药。化合物2对肝癌具有显著的抑制活性，IC50值为4.12μM。化合物1和2良好的抗肿瘤活性，可以做为抗肿瘤药物开发的先导化合物，对我国海洋微生物药物资源的开发具有重要意义。
本发明的节菱孢Arthrinium sp.ZSDS1-F3，于2013年12月20日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)，地址：北京市朝阳区北辰西路1号院，中科院微生物研究所，邮编：100101，保藏编号为CGMCC No.8652。该菌株公开于专利申请号：CN201410021280.4，发明名称：吡啶酮生物碱类化合物及其制备方法和在制备抗肿瘤药物中的应用中。
附图说明
图1为化合物1和2主要的1H-1H COSY,HMBC和NOESY信息。
图2为化合物1的X-Ray单晶图。
图3为不同浓度下化合物1和2对三种肿瘤细胞株的增殖抑制活性。
具体实施方式
下面结合具体实施例对本发明作出进一步地详细阐述，所述实施例只用于解释本发明，并非用于限定本发明的范围。下述实施例中所使用的试验方法如无特殊说明，均为常规方法；所使用的材料、试剂等，如无特殊说明，为可从商业途径得到的试剂和材料。
实施例1：化合物1和2的制备及结构鉴定
1、制备节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物
每1000mL培养基是这样配制的：取山梨醇20g，麦芽糖20g，味精10g，蛋白胨3g，磷酸二氢钾0.5g，硫酸镁0.3g，然后溶于适量的水中，用水定容至1000mL，121℃高温灭菌30min，备用。将节菱孢Arthrinium sp.ZSDS1-F3接种到上述培养基中，28℃条件下摇床培养3天，得种子培养液，再以体积比5％的种子培养液接种到上述60L的培养基中，28℃条件下摇床培养12天，得到节菱孢Arthrinium sp.ZSDS1-F3的发酵产物。
2、化合物1和2的分离纯化
将上述节菱孢Arthrinium sp.ZSDS1-F3的发酵产物，以3600rpm离心，得上清发酵液和沉淀菌丝体。上清发酵液用乙酸乙酯等体积萃取3次，乙酸乙酯萃取液在低于40℃减压浓缩得发酵液浸膏；沉淀菌丝体用体积分数为85％的丙酮水溶液超声浸提，提取液经减压蒸馏后，再用乙酸乙酯反复萃取三次，乙酸乙酯萃取液在低于40℃下减压浓缩得菌丝体浸膏；合并发酵液浸膏和菌丝体浸膏，再用石油醚溶剂反复萃取三次，除去油脂部分，最后得约54.7g粗浸膏。该粗浸膏用正相硅胶柱层析分离，经拌样、干法装柱后，采用CH2Cl2-MeOH(0-100％,v/v)梯度洗脱顺序得7个组分(fr1～fr7)。组分fr4(CH2Cl2:MeOH＝95:5v/v洗脱的组分)经Sephadex LH-20柱层析，以甲醇为洗脱剂，洗脱纯化后，根据薄层层析结果分析，获得6个馏分(fr4-1～fr4-6)；收集以二氯甲烷：甲醇＝10：1v/v作为展开剂位移值在0.4-0.6范围内的馏分fr4-3，馏分fr4-3以210、290和340nm波长做检测、采用4mL/min的流速，以乙腈：水(55:45,v/v)进行等梯度洗脱进行半制备高效液相分离，HPLC(YMC-pack ODS-A,10×250mm,5μm)，得到化合物2(4.1mg，保留时间tR 19.2min)和化合物1(3.1mg，保留时间tR28.3min)。
3、化合物1和2的结构鉴定
对获得的化合物1和2进行核磁共振(NMR)、质谱(MS)、旋光(OR)、单晶衍射(X-Ray)等数据测试，从而确定化合物的化学结构。
新化合物1结构鉴定：无色晶体，高分辨质谱HRESIMS m/z 468.1991[M+Na]+(calcd for C24H31NNaO7,468.1993)，建议分子式为C24H31NO7；1H和13C NMR数据见表1，化合物1的NMR数据与已知化合物N-hydroxyapiosporamide的NMR数据非常相似，只有部分(环己烷片段)信号不同：13C NMR图谱中化合物1的C-21和C-22化学位移相对于已知化合物N-hydroxyapiosporamide向低场移动，表明环己烷片段中三元环氧打开，变为邻位二醇结构。此外，H-23与C-20的关键HMBC相关信号，表明C-20和C-23通过氧原子醚键相连。进一步通过X-Ray证明上述推断的正确性，同时确定了整个分子的绝对构型为3R 5S 8R 9R10R 20S21S 22S 23S，为结构崭新的化合物，命名为arthpyrone M。化合物1主要的COSY和HMBC相关信息见图1，化合物1的单晶X-Ray图见图2。
新化合物2结构鉴定：淡黄色油状物，高分辨质谱HRESIMS m/z 452.2040[M+Na]+(calcd for C24H31NNaO6,430.2043)，建议分子式为C24H31NO6；1H和13C NMR数据见表1，化合物2的NMR数据与化合物1的NMR数据非常相似，同样不同核磁数据主要发生在环己烷片段之处：二维核磁谱图COSY中可以发现关键的H-20/H2-25/H2-24/H-23/H-22自选耦合体系。HMBC中发现H-23和H2-25与羰基碳信号C-21的关键相关信号。经检索，化合物2为崭新结构，命名为arthpyrone N。化合物2主要的COSY和HMBC相关信息见图1。
表1.化合物1和2的1H和13C NMR数据(CD3OD,500MHz)
根据以上理化数据分析可知，化合物1和化合物2的具体结构如式(Ⅰ)所示。
实施例2：化合物1和2的抗肿瘤活性检测
采用国际通用的肿瘤细胞株，即：人前列腺癌细胞(C42B)、人肺癌细胞(H446)、人肝癌细胞(HepG2)。以抗肿瘤药物5-氟尿嘧啶(5-FU)、恩杂鲁胺(Enzalutamide)、顺铂(DDP)、阿霉素(DOX)作为阳性对照。试验方法为国际通用的CCK-8法。
化合物1和2对上述三种肿瘤细胞的抑制活性数据如表2和图3所示。
表2.化合物1和2对四株肿瘤细胞的增殖抑制作用(IC50,μM)
上述实验结果表明，化合物1和2作为结构新颖的4-羟基-2-吡啶酮生物碱类衍生物，具有显著的抗肿瘤活性；特别是化合物1对前列腺癌肿瘤表现出显著的抗肿瘤活性，体外抗肿瘤细胞活性IC50值强于阳性药，可以做为抗肿瘤药物开发的先导化合物。对我国海洋微生物药物资源的开发具有重要意义。
以上仅是本发明的优选实施方式，应当指出的是，上述优选实施方式不应视为对本发明的限制，本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说，在不脱离本发明的精神和范围内，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (8)
1.4-羟基-2-吡啶酮生物碱类衍生物或其药用盐，其结构式如式1-2任一所示：
2.一种制备权利要求1所述的4-羟基-2-吡啶酮生物碱类衍生物的方法，其特征在于，所述的4-羟基-2-吡啶酮生物碱类衍生物是从节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物中分离制备得到的；具体步骤如下：
1)制备节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物；
2)对发酵培养物进行离心，得上清发酵液和沉淀菌丝体；上清发酵液用乙酸乙酯萃取，乙酸乙酯萃取液减压浓缩得到发酵液浸膏；沉淀菌丝体用丙酮水溶液超声浸提，提取液经减压蒸馏后，再用乙酸乙酯萃取，乙酸乙酯萃取液减压浓缩得到菌丝体浸膏；合并发酵液浸膏和菌丝体浸膏，再用石油醚反复萃取，除去油脂部分，得到粗浸膏；粗浸膏用正相硅胶柱层析分离，采用CH2Cl2-MeOH按体积分数0-100％进行梯度洗脱顺序得到组分7个组分fr1～fr7；将CH2Cl2-MeOH按体积比95:5洗脱得到的组分fr4经Sephadex LH-20柱层析，以甲醇为洗脱剂，洗脱纯化后，根据薄层层析结果分析，获得6个馏分fr4-1～fr4-6；收集以二氯甲烷：甲醇＝10：1v/v作为展开剂位移值在0.4-0.6范围内的馏分fr4-3，馏分fr4-3以210、290和340nm波长做检测、采用4mL/min的流速，以乙腈：水体积比为55:45进行等梯度洗脱进行半制备高效液相分离，收集保留时间为19.2min的组分，得到化合物2，收集保留时间为28.3min的组分，得到化合物1。
3.根据权利要求2所述的制备方法，其特征在于，所述的节菱孢Arthrinium sp.ZSDS1-F3的发酵培养物是将节菱孢Arthrinium sp.ZSDS1-F3接入发酵培养基中发酵得到，所述的发酵培养基，每升含有：山梨醇20g，麦芽糖20g，味精10g，蛋白胨3g，磷酸二氢钾0.5g，硫酸镁0.3g，溶剂为水。
4.权利要求1所述的4-羟基-2-吡啶酮生物碱类衍生物或其药用盐在制备抗肿瘤药物中的应用。
5.根据权利要求4所述的应用，其特征在于，所述的抗肿瘤药物为抗前列腺癌、肺癌或肝癌的药物。
6.根据权利要求5所述的应用，其特征在于，当为化合物1时，所述的抗肿瘤药物为抗前列腺癌的药物。
7.一种抗肿瘤药物，其特征在于，包含有效量的作为活性成分的权利要求1中式1-2任一所示的4-羟基-2-吡啶酮生物碱类衍生物或其药用盐，和药学上可以接受的载体。
8.节菱孢Arthrinium sp.ZSDS1-F3在制备权利要求1所述的4-羟基-2-吡啶酮生物碱类衍生物中的应用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022114112948 | 2022-11-11 | ||
| CN202211411294 | 2022-11-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116082358A CN116082358A (zh) | 2023-05-09 |
| CN116082358B true CN116082358B (zh) | 2024-03-26 |
Family
ID=86202109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310041169.0A Active CN116082358B (zh) | 2022-11-11 | 2023-01-12 | 一类4-羟基-2-吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116082358B (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009091A2 (en) * | 2008-07-14 | 2010-01-21 | Herbalscience Group, Llc | Anti-inflammatory and anti-allergy extracts from nettle |
| CN103951617A (zh) * | 2014-01-16 | 2014-07-30 | 中国科学院南海海洋研究所 | 吡啶酮生物碱类化合物及其制备方法和在制备抗肿瘤药物中的应用 |
| CN103948592A (zh) * | 2014-01-16 | 2014-07-30 | 中国科学院南海海洋研究所 | 生物碱类化合物在制抗肠道病毒及乙酰胆碱酯酶抑制剂药物中的应用 |
| CN108441427A (zh) * | 2018-03-15 | 2018-08-24 | 济南大学 | 一种节菱孢属真菌及其生产的吡啶酮生物碱类化合物 |
-
2023
- 2023-01-12 CN CN202310041169.0A patent/CN116082358B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010009091A2 (en) * | 2008-07-14 | 2010-01-21 | Herbalscience Group, Llc | Anti-inflammatory and anti-allergy extracts from nettle |
| CN103951617A (zh) * | 2014-01-16 | 2014-07-30 | 中国科学院南海海洋研究所 | 吡啶酮生物碱类化合物及其制备方法和在制备抗肿瘤药物中的应用 |
| CN103948592A (zh) * | 2014-01-16 | 2014-07-30 | 中国科学院南海海洋研究所 | 生物碱类化合物在制抗肠道病毒及乙酰胆碱酯酶抑制剂药物中的应用 |
| CN108441427A (zh) * | 2018-03-15 | 2018-08-24 | 济南大学 | 一种节菱孢属真菌及其生产的吡啶酮生物碱类化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116082358A (zh) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111139188B (zh) | 一株海洋真菌来源的新型骨架杂萜衍生物及其在制备抗炎药物中的应用 | |
| CN112142819B (zh) | 白桦脂酸衍生物在制备抗肿瘤药物中的应用 | |
| CN109942658B (zh) | 一类杂萜化合物及其制备方法与应用和抗肿瘤的药物 | |
| CN116082358B (zh) | 一类4-羟基-2-吡啶酮生物碱类衍生物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN113248369A (zh) | 具有抗新冠病毒活性的聚酮类化合物的制备及其应用 | |
| CN109985044B (zh) | 白桦醇及其衍生物在制备抗肿瘤药物中的应用 | |
| CN115403556B (zh) | 戊酮噻吩类化合物及其制备方法和在抗炎药物中的应用 | |
| CN113603594B (zh) | 倍半萜类化合物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN112500348B (zh) | 一类格尔德霉素衍生物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN114716312B (zh) | 半日花烷型二萜化合物及其制备方法与应用 | |
| CN114213428B (zh) | 一种吲哚生物碱化合物及其制备方法和应用 | |
| Clark et al. | Production of a novel dimeric metabolite of primaquine by Streptomyces rimosus | |
| CN110452940B (zh) | 一种链霉菌的次级代谢产物的分离提取方法 | |
| CN111217878A (zh) | 一类andrastone类化合物及其制备方法以及在制备抗过敏药物中的应用 | |
| CN114230538B (zh) | 一种环系蒽醌类化合物及其制备方法和应用 | |
| CN111205308B (zh) | 一种硫代二酮哌嗪类化合物及其制备方法和应用 | |
| CN113480557B (zh) | 聚酮类化合物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN116874417B (zh) | 一种吡啶类生物碱及其在抗肿瘤药物制备中的应用 | |
| CN116041305B (zh) | 青霉菌（Penicillium mali）的发酵化合物及其制备方法和抗肿瘤应用 | |
| CN118652180A (zh) | 一种芳香族聚酮类化合物及其制备方法和对ptp1b的抑制活性和抗肿瘤活性的应用 | |
| CN118652179A (zh) | 一种新的芳香族聚酮类化合物及其制备方法和用途 | |
| CN116554187A (zh) | 一种新颖骨架类型细胞松弛素及其在制备具有抗肿瘤活性的药物中的应用 | |
| CN106011190B (zh) | 一种天然对氨基苯甲酸及其衍生物的制备方法 | |
| CN118702666A (zh) | 一种多羟基氧杂蒽酮类化合物及其制备方法和应用 | |
| CN114989117A (zh) | 一种季酮酸类化合物的提取方法及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |